We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-2.48%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.43B
AUM Growth
+$280M
Cap. Flow
-$9.04M
Cap. Flow %
-0.37%
Top 10 Hldgs %
37.47%
Holding
114
New
20
Increased
14
Reduced
20
Closed
12

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$49M
2
LCI
Lannett Company, Inc.
LCI
+$46.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$45.7M
4
ELV icon
Elevance Health
ELV
+$42.6M
5
CNC icon
Centene
CNC
+$35.6M

Top Sells

Rank Stock Value
1
DVA icon
DaVita
DVA
+$23.1M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$19.2M
3
SEM
Select Medical
SEM
+$18.3M
4
TSRO
TESARO, Inc.
TSRO
+$16.4M
5
AET
Aetna Inc
AET
+$14.8M

Sector Composition

Rank Sector Weight
1 Healthcare 69.33%
2 Financials 2.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
51
DELISTED
Alpine Immune Sciences Inc
ALPN
$8.36M 0.34%
933,103
– –
AKTX
52
Akari Therapeutics
AKTX
$20.1M
$8.1M 0.33%
1,438
– –
LOXO
53
DELISTED
Loxo Oncology, Inc
LOXO
$8.06M 0.33%
251,000
– –
OXFD
54
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$7.91M 0.33%
529,197
+64,656
+14% +$908K
KERX
55
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$7.57M 0.31%
+1,291,531
New +$7.06M
ARLZ
56
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$7.25M 0.3%
1,644,583
– –
SIOX
57
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$7.05M 0.29%
71,001
– –
FPRX
58
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$6.92M 0.28%
138,000
-173,000
-56% -$9.09M
EXAS
59
DELISTED
Exact Sciences
EXAS
$6.68M 0.27%
500,000
+142,320
+40% +$2.3M
ALIM
60
DELISTED
Alimera Sciences
ALIM
$6.35M 0.26%
391,868
– –
AAAP
61
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$5.62M 0.23%
+210,000
New +$7.06M
MYOK
62
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$5.5M 0.23%
424,800
-75,000
-15% -$1.16M
ARDX icon
63
Ardelyx
ARDX
$1.27B
$5.31M 0.22%
373,643
-245,000
-40% -$3.48M
CASM
64
DELISTED
CAS Medical Systems, Inc.
CASM
$5.15M 0.21%
3,200,000
– –
RARX
65
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$4.92M 0.2%
+323,630
New +$4.4M
EPIX
66
DELISTED
ESSA Pharma
EPIX
$4.65M 0.19%
106,080
– –
STDY
67
DELISTED
SteadyMed Ltd
STDY
$4.57M 0.19%
1,756,370
– –
SCYX icon
68
SCYNEXIS
SCYX
$39M
$3.34M 0.14%
13,100
– –
ZVRA icon
69
Zevra Therapeutics
ZVRA
$732M
$3.2M 0.13%
67,778
– –
NSTG
70
DELISTED
NanoString Technologies, Inc.
NSTG
$3.1M 0.13%
139,000
-87,691
-39% -$1.88M
VYGR icon
71
Voyager Therapeutics
VYGR
$187M
$3M 0.12%
235,294
– –
GNCA
72
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.83M 0.12%
85,907
– –
SGMO
73
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.56M 0.11%
+837,963
New +$3.05M
EYPT icon
74
EyePoint Inc
EYPT
$1.07B
$2.55M 0.11%
149,282
– –
TARA icon
75
Protara Therapeutics
TARA
$230M
$2.53M 0.1%
33,315
-5,947
-15% -$1.88M
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2016 Portfolio in Review

As of Q4 2016, Deerfield Management held 114 positions worth $2.43B, up 13% from $2.15B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Deerfield Management's Q4 2016 filing shows 20 new, 14 increased, 20 reduced and 12 closed positions. Its largest new stake was Lannett Company, Inc.: 501,888 shares worth $44.3M. The largest sale was DaVita, an estimated $23.1M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 70% a quarter earlier, followed by Financials.

  • Deerfield Management's largest Q4 2016 buy was Lannett Company, Inc.: 501,888 shares worth $44.3M.
  • Deerfield Management added most to Blueprint Medicines in Q4 2016, an estimated $49M increase.
  • Deerfield Management's biggest Q4 2016 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $19.2M.
  • Deerfield Management fully exited DaVita in Q4 2016, selling an estimated $23.1M.
  • Deerfield Management's ten largest holdings make up 37% of its $2.43B portfolio in Q4 2016.
  • Deerfield Management opened 20 new positions and closed 12 in Q4 2016.
  • Deerfield Management's portfolio value rose 13% quarter-over-quarter to $2.43B.

Based on Deerfield Management's 13F filing for Q4 2016, filed 14 Feb 2017.